Bisgrove Dwayne, Lewinski Mary, Bushman Frederic, Verdin Eric
Gladstone Institute of Virology and Immunology, University of California, San Francisco, CA 94158, USA.
Expert Rev Anti Infect Ther. 2005 Oct;3(5):805-14. doi: 10.1586/14787210.3.5.805.
While great strides have been made in the treatment of HIV infection with highly active antiretroviral therapy, an actual cure remains out of grasp. One confounding factor is the persistence of a small population of infected cells containing transcriptionally silent but reactivatable HIV proviruses. Following cessation of highly active antiretroviral therapy, these latently-infected cells serve as an inoculum for re-establishing an active infection. Recent progress in our understanding of the molecular mechanisms underlying HIV proviral latency will be reviewed. Recent advances in the study of transcriptional regulation and the completion of the Human Genome Project underscore the role of chromatin and the site of viral integration on HIV transcription. Finally, experimental therapies designed to eliminate the latent population will be highlighted.
尽管高效抗逆转录病毒疗法在治疗HIV感染方面取得了巨大进展，但真正的治愈仍然遥不可及。一个令人困惑的因素是一小部分受感染细胞的持续存在，这些细胞含有转录沉默但可重新激活的HIV前病毒。在高效抗逆转录病毒疗法停止后，这些潜伏感染的细胞成为重新建立活跃感染的接种物。本文将综述我们对HIV前病毒潜伏背后分子机制理解的最新进展。转录调控研究的最新进展以及人类基因组计划的完成强调了染色质和病毒整合位点对HIV转录的作用。最后，将重点介绍旨在消除潜伏群体的实验性疗法。
